BCR Pathway Assay (CAT#: STEM-MB-0344-WXH)

Signals from signal bodies activate multiple signal cascades, including kinases, GTPases, and transcription factors. This will lead to changes in cell metabolism, gene expression and cytoskeletal structure. The complexity of BCR signal transduction can lead to many distinct outcomes, including survival, tolerance (disability) or apoptosis, proliferation, and differentiation into antibody-producing cells or memory B cells. The outcome of the response is determined by many factors, including the mature state of the cell, antigenic properties, the scope and duration of BCR signal transduction, and signals from other receptors (such as CD40, IL-21 receptor, and BAFF-R). Many other transmembrane proteins, some of which are also receptors, can modulate specific parts of BCR signal transduction. Some of these transmembrane proteins include CD45, CD19, CD22, PIR-B and FcγRIIB1 (CD32), which are marked in yellow here. The scope and duration of BCR signal transduction are limited by the negative feedback loop, which includes Lyn/CD22/SHP-1 pathway, Cbp/Csk pathway, SHIP, Cbl, Dok-1, Dok-3, FcγRIIB1, PIR-B And internalization of BCR.

To study the effects of drugs or therapies on B cell receptor signaling pathways
To study the effect of each virus on B cell receptor signaling pathway
To study the regulation mechanism of B cell receptor signaling pathway in disease

• Luminex Multiplex Assay
• Enzyme-linked immunosorbent assay (ELISA)
• Flow cytometry (FACS analysis) technology

Detectable targets: SHP2, PIP3, FGR2B, Lyn, CD22, CD19, CD45, PIR-B, Etk, PTEN, Dok3, Akt, PKC, LAB, SOS, Plcy2, Syk, CSK, cdc42, GSK3, TAK1, NFκB, NFAT, c-Raf, JNK1, JNK2, MEK1, p85, Erk1, Erk2, CaM, CD40, MEK2, p38, SHIP, JNK, IKK, HS1, IkB, p70S6K, Cbl, HS1, mTOR, Vav, PI3K, p110, Rap, MEKK